Related Experiment Video
Updated: Jul 5, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase
Akinori Yoda1, Kyoko Toyoshima, Yasuhide Watanabe
1Department of Physiology and Cell Biology, Faculty of Medical Sciences, Graduate School of Medicine, Kobe University, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
Abstract:
The oncogenic Wip1 phosphatase (PPM1D) is induced upon DNA damage in a p53-dependent manner and is required for inactivation or suppression of DNA damage-induced cell cycle checkpoint arrest and of apoptosis by dephosphorylating and inactivating phosphorylated Chk2, Chk1, and ATM kinases. It has been reported that arsenic trioxide (ATO), a potent cancer chemotherapeutic agent, in particular for acute promyelocytic leukemia, activates the Chk2/p53 pathway, leading to apoptosis. ATO is also known to activate the p38 MAPK/p53 pathway. Here we show that phosphatase activities of purified Wip1 toward phosphorylated Chk2 and p38 in vitro are inhibited by ATO in a dose-dependent manner. Furthermore, DNA damage-induced phosphorylation of Chk2 and p38 in cultured cells is suppressed by ectopic expression of Wip1, and this Wip1-mediated suppression can be restored by the presence of ATO. We also show that treatment of acute promyelocytic leukemia cells with ATO resulted in induction of phosphorylation and activation of Chk2 and p38 MAPK, which are required for ATO-induced apoptosis. Importantly, this ATO-induced activation of Chk2/p53 and p38 MAPK/p53 apoptotic pathways can be enhanced by siRNA-mediated suppression of Wip1 expression, further indicating that ATO inhibits Wip1 phosphatase in vivo. These results exemplify that Wip1 is a direct molecular target of ATO.
Insights
Arsenic trioxide (ATO) inhibits the Wip1 phosphatase, a key regulator of DNA damage responses. This inhibition is crucial for ATO
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- The Wip1 phosphatase (PPM1D) is an oncogene induced by DNA damage, suppressing cell cycle arrest and apoptosis by dephosphorylating key kinases like Chk2, Chk1, and ATM.
- Arsenic trioxide (ATO), a chemotherapeutic agent, activates the Chk2/p53 and p38 MAPK/p53 pathways, inducing apoptosis, particularly in acute promyelocytic leukemia.
Purpose of the Study:
- To investigate the direct molecular interaction between arsenic trioxide (ATO) and Wip1 phosphatase.
- To elucidate the role of Wip1 inhibition in ATO-mediated cancer cell apoptosis.
Main Methods:
- In vitro assays using purified Wip1 and phosphorylated substrates (Chk2, p38).
- Cell culture experiments involving ectopic Wip1 expression and ATO treatment.
- siRNA-mediated Wip1 suppression in acute promyelocytic leukemia cells.
- Analysis of Chk2 and p38 MAPK phosphorylation and activation.
Main Results:
- ATO directly inhibits Wip1 phosphatase activity in a dose-dependent manner in vitro.
- Ectopic Wip1 suppresses DNA damage-induced Chk2 and p38 phosphorylation, an effect reversed by ATO.
- ATO treatment induces Chk2 and p38 MAPK phosphorylation and activation in acute promyelocytic leukemia cells.
- Wip1 suppression enhances ATO-induced apoptosis, confirming in vivo inhibition of Wip1 by ATO.
Conclusions:
- Wip1 phosphatase is a direct molecular target of arsenic trioxide (ATO).
- ATO's inhibition of Wip1 contributes to the activation of apoptotic pathways, enhancing its anti-cancer efficacy.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...